 Connection
Ping-Ching Hsu to Neoplasm Staging
This is a "connection" page, showing publications Ping-Ching Hsu has written about Neoplasm Staging.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.113 |
|
|
|
-
Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.
Score: 0.040
-
Chu CH, Chiu TH, Wang CC, Chang WC, Huang AC, Liu CY, Wang CL, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. Thorac Cancer. 2020 06; 11(6):1541-1549.
Score: 0.037
-
Huang SH, Huang AC, Wang CC, Chang WC, Liu CY, Pavlidis S, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thorac Cancer. 2019 12; 10(12):2274-2281.
Score: 0.036
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|